




# PHARMACEUTICAL 2021

Xenetic Biosciences Inc.  
Rank 155 of 402





# PHARMACEUTICAL 2021

Xenetic Biosciences Inc.  
Rank 155 of 402



The relative strengths and weaknesses of Xenetic Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenetic Biosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Xenetic Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 143%, being 96% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	12,370
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	937
Liabilities, Non-Current	0
Other Assets	810
Other Compr. Net Income	0
Other Expenses	6,325
Other Liabilities	27
Other Net Income	126
Other Revenues	437
Property and Equipment	0
Research and Development	1,731
Selling, General and Administrative Expense	3,400

Output Variable	Value in 1000 USD
Assets	13,179
Liabilities	964
Expenses	11,456
Revenues	437
Stockholders Equity	12,216
Net Income	-10,893
Comprehensive Net Income	-10,893
Economic Capital Ratio	143%